Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model

Varghese, Bindu; Lynch, Lydia; Vriend, Lianne; Clark, Justice; Varghese, Sharlin; Sanda, Martin G.; Dranoff, Glenn; Arredouani, Mohammed S.; Balk, Steven P.; Exley, Mark A.

doi:10.1007/s00262-022-03210-8

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…increases vaccine immunogenicity (52)(53)(54). Cancer vaccines often lack immunogenicity and therefore could possibly benefit from this approach, as already shown for NKT cells (55)(56)(57).…”

Section: Mait Cells As Adjuvants For Vaccine Immunologymentioning

confidence: 99%

Mucosal-associated invariant T cells in hematological malignancies: Current knowledge, pending questions

Treiner

2023

Front. Immunol.

View full text Add to dashboard Cite

Non-classical HLA restricted T cell subsets such as γδ T and NK-T cells are showing promises for immune-based therapy of hematological malignancies. Mucosal-Associated Invariant T cells (MAIT) belong to this family of innate-like T cell subsets and are the focus of many studies on infectious diseases, owing to their unusual recognition of bacterial/fungal metabolites. Their ability to produce type 1 cytokines (IFNγ, TNFα) as well as cytotoxic effector molecules endows them with potential anti-tumor functions. However, their contribution to tumor surveillance in solid cancers is unclear, and only few studies have specifically focused on MAIT cells in blood cancers. In this review, we wish to recapitulate our current knowledge on MAIT cells biology in hematological neoplasms, at diagnosis and/or during treatment, as well as tentative approaches to target them as therapeutic tools. We also wish to take this opportunity to briefly elaborate on what we think are important question to address in this field, as well as potential limitations to overcome in order to make MAIT cells the basis of future, novel therapies for hematological cancers.

show abstract

Section: Mait Cells As Adjuvants For Vaccine Immunologymentioning

confidence: 99%

Mucosal-associated invariant T cells in hematological malignancies: Current knowledge, pending questions

Treiner

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Targeting cytokine and chemokine signaling pathways for cancer therapy

Yi,

Li,

Niu

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Cytokines are critical in regulating immune responses and cellular behavior, playing dual roles in both normal physiology and the pathology of diseases such as cancer. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, and growth factors like TGF-β, VEGF, and EGF, can promote or inhibit tumor growth, influence the tumor microenvironment, and impact the efficacy of cancer treatments. Recent advances in targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate the immune system, inhibit tumor progression, and overcome resistance to conventional therapies. In this review, we summarized the current understanding and therapeutic implications of targeting cytokine and chemokine signaling pathways in cancer. By exploring the roles of these molecules in tumor biology and the immune response, we highlighted the development of novel therapeutic agents aimed at modulating these pathways to combat cancer. The review elaborated on the dual nature of cytokines as both promoters and suppressors of tumorigenesis, depending on the context, and discussed the challenges and opportunities this presents for therapeutic intervention. We also examined the latest advancements in targeted therapies, including monoclonal antibodies, bispecific antibodies, receptor inhibitors, fusion proteins, engineered cytokine variants, and their impact on tumor growth, metastasis, and the tumor microenvironment. Additionally, we evaluated the potential of combining these targeted therapies with other treatment modalities to overcome resistance and improve patient outcomes. Besides, we also focused on the ongoing research and clinical trials that are pivotal in advancing our understanding and application of cytokine- and chemokine-targeted therapies for cancer patients.

show abstract

Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model

Cited by 2 publications

References 49 publications

Mucosal-associated invariant T cells in hematological malignancies: Current knowledge, pending questions

Mucosal-associated invariant T cells in hematological malignancies: Current knowledge, pending questions

Targeting cytokine and chemokine signaling pathways for cancer therapy

Contact Info

Product

Resources

About